No Data
Zhuhai International: The pharmaceutical industry in China is expected to continue the valuation recovery this year, with the market for Innovative Drugs likely to differentiate.
Zhao Yin International published a report indicating that, driven by positive factors such as the export Trade of Innovative Drugs, optimization of domestic procurement policies, the implementation of the Class B medical insurance catalog for Innovative Drugs, the revival of tenders for Medical Devices, and the recovery of domestic demand, the Pharmaceutical Industry is expected to continue experiencing valuation repair in 2025.
Hong Kong Stock Movement | Giant Biotechnology (02367) rises nearly 3%. Institutions indicate that China's restructuring of collagen globalization is accelerating and suggest paying attention to the layout of industry leaders.
Giant Biotechnology (02367) rose nearly 3%, as of the time of writing, it increased by 2.46%, priced at 78.95 Hong Kong dollars, with a transaction amount of 0.103 billion Hong Kong dollars.
CITIC SEC: China's restructuring of collagen globalization accelerates, with "raw materials, cosmetics, and equipment" going global comprehensively.
CITIC SEC released a Research Report stating that the restructured collagen Industry continues to make progress in technology and processes, achieving breakthroughs in type XVII, type IV, and various combinations following types I and III; leading companies have become more mature in their capabilities for structural analysis, fermentation preparation, productization, and commercialization.
Shareholders of Giant Bio (02367) will transfer their stocks from Goldman Sachs (Asia) Securities to Citibank, with a Market Cap of 2.607 billion HKD.
On April 23, the shareholders of Juzi Biotechnology (02367) transferred the stocks from Goldman Sachs (Asia) Securities to Citibank, with a market cap of 2.607 billion HKD, accounting for 3.28%.
Statistics on Capital Trend for Stock Connect (T+2) | April 24
Capital Trend of the Hong Kong Stock Connect | April 24th
Hong Kong stock market movement | Goliath Biotech (02367) rose more than 5% in the morning session, and the Shaanxi Provincial Drug Administration reported that multiple batches of Kefu Mei products did not detect EGF.
Giant Biotech (02367) rose more than 5% in early trading, as of the time of writing, it is up 4.44%, reported at 75.3 Hong Kong dollars, with a transaction amount of 0.422 billion Hong Kong dollars.
